Can You Switch from Mounjaro Injections to the Wegovy Pill? Dose & Washout Guide

Key Takeaways

Because Mounjaro (tirzepatide) and the Wegovy pill (semaglutide) are distinct drugs, clinicians wait 7 days after your final weekly injection before starting your first morning tablet.
Moving from dual GIP/GLP-1 tirzepatide (~20% trial loss) to single-agonist oral semaglutide (~14–17% trial loss) works particularly well for needle-free long-term maintenance.
Expect a brief 2–4 week digestive and appetite adjustment window while semaglutide builds steady levels.

Many patients who reach their goal weight — or grow tired of weekly needles and cold-chain travel — ask whether they can transition from Mounjaro (tirzepatide) to the Wegovy pill (oral semaglutide). With clinician oversight and a 7-day washout gap after your final pen dose, switching is straightforward.

Clinical dose-matching chart: Mounjaro pen → Wegovy daily pill

Current Weekly Mounjaro Dose	Typical Starting Daily Wegovy Pill	Gap After Last Injection
2.5mg weekly	1.5mg daily	7 days
5mg weekly	4mg daily	7 days
7.5mg weekly	9mg daily	7 days
10mg weekly	9mg daily	7 days
12.5mg – 15mg weekly	9mg or 25mg daily (clinician-assessed)*	7 days

*Stepping directly to 25mg carries a slightly higher transient GI side-effect rate; many prescribers bridge via 9mg for 30 days first.

What to expect after switching

Because Mounjaro activates both GIP and GLP-1 receptors (~20% average 72-week weight loss in SURMOUNT-1) whereas oral Wegovy activates GLP-1 alone (~14%–17% in OASIS-4) (1,2), some patients notice slightly gentler appetite suppression unless they follow oral Wegovy’s strict morning empty-stomach routine (3). If you are thriving on Mounjaro and still actively losing toward a high target, staying on tirzepatide may maximize momentum; if you want needle-free maintenance, speak with a clinical prescriber to plan a smooth transition.

References

Jastreboff AM, et al. Tirzepatide Once Weekly for Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205–16.
Wharton S, Lingvay I, et al. Oral Semaglutide 25 mg in Obesity (OASIS-4). N Engl J Med. 2025;393(11):1077–87.
Novo Nordisk. Wegovy Prescribing Information. 2026.

Medical Editorial Review: Reviewed by the Amble Clinical Editorial Team. This article is for educational purposes only and does not replace an individualized consultation with a licensed healthcare professional.

Related Clinical Guides

GLP-1 & Weight Loss · 9 minComparing Mounjaro Costs by Dose: What Full-Year Treatment Actually CostsMounjaro costs scale across six strengths from 2.5mg to 15mg — meaning provider choice, included supplies, and maintenance dosing can create more than a $750 annual difference.GLP-1 & Weight Loss · 6 minWhat Is the 'Golden Dose' of Mounjaro — and Why You Shouldn't Use ItSocial media posts often call the priming liquid left inside a Mounjaro pen after four injections the 'golden 5th dose.' Here is why extracting it risks inaccurate dosing and contamination.GLP-1 & Weight Loss · 6 minOrforglipron (Foundayo) Cost Guide: What Daily GLP-1 Tablets CostFoundayo (orforglipron) offers needle-free GLP-1 weight loss in a once-daily small-molecule tablet. Explore how tablet strengths, titration packs, and clinical care shape monthly pricing.

Your personalizedweight care plan

Clinician-prescribed GLP-1 & metabolic care, 100% online.

Get started